Comfortable leader
10 companies value 93 bn revenue 50 bn margin -7.6% free cash flow 4.3 bn avg. score 3.5
TEVA holds 51.7% of the group's value, 2.3x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical Israel · score 5.2 | 52% | 48 bn | 17 bn | 4.1% | 1.4 bn | 2.8% | — | Generic and specialty drugs, from Israel · World's largest generic drugmaker | |
| 2 | VTRS | Viatris United States · score 3.5 | 23% | 21 bn | 15 bn | -23.9% | 1.9 bn | 9.3% | — | Generic and branded drugs at global scale · Born from Mylan + Upjohn; a global generics portfolio with a high yield | |
| 3 | RDY | DR REDDYS LABORATORIES LTD India · score 5.8 | 12% | 11 bn | 3.6 bn | 12.6% | 0.4 bn | 3.3% | 0.7% | Pharma with licensed products in many countries · India — revenue of $3.6bn | |
| 4 | AMRX | Amneal Pharmaceuticals, Inc. United States · score 4.1 | 7% | 6.2 bn | 3.1 bn | 5.0% | 0.1 bn | 2.1% | — | Global biopharma of essential medicines · New Jersey — revenue of $3.1bn | |
| 5 | OGN | Organon United States · score 5.4 | 4% | 3.6 bn | 6.1 bn | 3.4% | 0.6 bn | 15.7% | 0.5% | Women's health medicines and biosimilars · Women's health and mature brands, spun off from Merck | |
| 6 | PRGO | Perrigo Ireland · score 3.1 | 2% | 2.2 bn | 4.1 bn | -41.9% | 0.1 bn | 5.3% | 7.2% | Store-brand over-the-counter medicines · Largest maker of store-brand medicines for pharmacies | |
| 7 | AMPH | Amphastar Pharmaceuticals, Inc. United States · score 6.1 | 1% | 1.1 bn | 0.7 bn | 10.8% | 0.1 bn | 13.8% | — | Pharma for injectables and active ingredients · California — revenue of $730m | |
| 8 | AEON | AEON Biopharma, Inc. United States · score 0.5 | 0% | 0.0 bn | — | — | -0.0 bn | -118.7% | — | Biopharma of a biosimilar botulinum toxin · California | |
| 9 | ALVO | Alvotech Luxembourg · score 0.0 | — | — | 0.5 bn | -36.5% | -0.3 bn | — | — | Development and manufacturing of biosimilars (versions of Humira, Stelara, Eylea and others) in Iceland · Luxembourg — revenue of $492m | |
| 10 | SBFM | Sunshine Biopharma Inc. United States · score 1.2 | — | — | 0.0 bn | -16.5% | -0.0 bn | — | — | Drug licensing and distribution in Canada · Florida — revenue of $35m |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
and 22 industries more
- Molecular testing and advanced diagnostics 42 companies
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.